A second update and the SP remains around .17.

EFSF does communicate but there are no figures. I'd like to see if there are revenues, if there is a product that bring more than it cost to produce and advertise.

The new update is good anyway. I hope it will become a habit. I hope to see positive launches rather than -soon- or -1 to 2 months-. Cinnergen and Cinnechol are a disappointment to date. Are we lacking funds to conducts a real ad campain? Like, trying to reach too many people rather than concentrating on certain areas?

IMO, a good buy under .20. Something is bound to happen. Read about DuPont and OraPhyte, for example.

go